[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349704-105":59,"doc-detail-349704-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-recycling-collagen-receptor-uparap-is-a-unique-mediator-of-stromal-drug-delivery-to-carcinoma-cells","The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells","","Cancer-associated fibroblasts (CAFs) infiltrate carcinomas yet are genetically stable, while cancer cells often develop resistance to targeted drugs. The study uses antibody–drug conjugates (ADCs) that exploit the rapidly recycling endocytic receptor uPARAP to drive efficient CAF-mediated delivery and killing of carcinoma cells. uPARAP is absent from carcinoma cells but expressed in restricted mesenchymal cancer types, and is highly expressed in CAFs across multiple carcinoma types. In mouse xenograft models, uPARAP-targeting ADCs eradicate tumors with clinically validated payloads and improve survival, while uPARAP-expressing fibroblasts remain responsive in vitro.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-recycling-collagen-receptor-uparap-is-a-unique-mediator-of-stromal-drug-delivery-to-carcinoma-cells/349704/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-recycling-collagen-receptor-uparap-is-a-unique-mediator-of-stromal-drug-delivery-to-carcinoma-cells/349704.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are cancer-associated fibroblasts (CAFs) important for stromal drug delivery?","Question",{"text":112,"@type":113},"CAFs infiltrate all carcinomas and are genetically stable, making them useful carriers for delivering cytotoxic therapy to tumor cells despite resistance mechanisms in cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the role of uPARAP in the described ADC strategy?",{"text":117,"@type":113},"uPARAP is a rapidly recycling endocytic receptor that enables highly efficient CAF-mediated drug delivery and killing. It is generally not present on carcinoma cells and is expressed in a restricted group of mesenchymal cancer cell types.",{"name":119,"@type":110,"acceptedAnswer":120},"How do bystander effects influence the effectiveness of ADC payloads?",{"text":121,"@type":113},"After release from dying cells, bystander-competent payloads can permeate neighboring cancer cells regardless of ADC target expression, helping overcome heterogeneity in target protein levels across tumor cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349704,1791185991,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells  \nKirstine S. Nørregaard1,2, Ida M. E. Larsen1,2, Henrik J. Jrgensen1,2, Michaela Hansen Blomquist1,2,  \nPinar Çakilkaya1,2, Virginia Metrangolo1,2, Alba Martinez Perlado1,2, Oliver Krigslund1,2, Henrik Grdsvoll1,2, Thomas T. Poulsen3, Dominik Mumberg3, Eric Santoni-Rugiu4,5, Lars H. Engelholm1,2, and Niels Behrendt1,2,5  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | The genetic instability of cancer cells leads to cellular resistance against most targeted cancer drugs. Cancer-associated fibroblasts (CAF) infiltrate all carcinomas and are genetically stable. Using antibody–drug conjugates (ADC), we exploit the unique properties of a rapidly recycling endocytic receptor, uPARAP, to achieve highly efficient CAF-mediated drug delivery and killing of carcinomas. This receptor is generally not present on carcinoma cells and is only expressed in a restricted group of mesenchymal cancer cell types, which are sensitive touPARAP-directed ADCs. However, we show that uPARAP is highly expressed in CAFs in all carcinoma types examined. This property is recapitulated in mouse xenograft carcinoma models. In these models, despite the absence of uPARAP on the carcinoma cells, uPARAP-targeting ADCs with clinically validated payloads, monomethyl auristatin E and deruxtecan, eradicated\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | tumors with remarkable efficiency. Systemic treatment with anti-uPARAP ADC led to the permanent eradication of tumorsin mice carrying subcutaneous xenografts with human EBC-1 lung carcinoma cells. A pronounced repression of tumor growth and a strongly increased mouse survival rate were also obtained with human HT29 colon adenocarcinoma cells, both when these tumors were growing subcutaneously and after the homing of tumor cells to bone from the circulation. CAFs were largely refractory to ADC treatment and retained a high expression of uPARAP. uPARAP-expressing fibroblasts could also process an anti-uPARAP ADC in vitro and deliver the cytotoxic component to carcinoma cells. The current bystander mechanism maybe exploited in the majority of the most prevalent solid cancers, thus making uPARAP an extraordinarily versatile target for ADC-based cancer treatment. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nAntibody–drug conjugates (ADC) are a rapidly advancing treatment modality for several cancer types. These drugs are at the center of targeted treatment strategies and stand out in their ability to specifically deliver highly efficient drugs to cancer cells. Thus, 13 ADCs are currently approved by the FDA, whereas many more are in clinical and preclinical development (1) . The basic principle in this treatment concept relies on the binding of a cytotoxinconjugated mAb to a target protein that is strongly upregulated on cancer cells. After bindin","cbCaiiqfbQRx0IxR","https://ap.wps.com/l/cbCaiiqfbQRx0IxR","pdf",38005184,16,"English","# Introduction\n## ADCs and targeted delivery\n## Bystander effect and challenges\n# uPARAP as a stromal delivery mediator\n## Receptor recycling and expression pattern\n## CAF-mediated killing in models","[{\"question\":\"Why are cancer-associated fibroblasts (CAFs) important for stromal drug delivery?\",\"answer\":\"CAFs infiltrate all carcinomas and are genetically stable, making them useful carriers for delivering cytotoxic therapy to tumor cells despite resistance mechanisms in cancer cells.\"},{\"question\":\"What is the role of uPARAP in the described ADC strategy?\",\"answer\":\"uPARAP is a rapidly recycling endocytic receptor that enables highly efficient CAF-mediated drug delivery and killing. It is generally not present on carcinoma cells and is expressed in a restricted group of mesenchymal cancer cell types.\"},{\"question\":\"How do bystander effects influence the effectiveness of ADC payloads?\",\"answer\":\"After release from dying cells, bystander-competent payloads can permeate neighboring cancer cells regardless of ADC target expression, helping overcome heterogeneity in target protein levels across tumor cells.\"}]","The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells | PDF",1790085129,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24e6a11eda35cb2eac0a5b45c1d45773.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6caeb323076b78dfa8fe15d65d445341.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f6dc05ee521a1ed8af8dc6eb0adc0ce.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba16011e62bae46a505e6a0932861312.webp",980,1311]